BIOGRAPHY

Michael Schultze

Dr. Michael Schultze leads a dedicated team of Real-World Evidence (RWE) experts in designing and implementing secondary data-driven non-interventional studies.
  • Michael Schultze

    Director of Real-World Evidence & Safety Data Analytics

Dr. Michael Schultze leads a dedicated team of Real-World Evidence (RWE) experts in designing and implementing secondary data-driven non-interventional studies.

Alongside his managerial responsibilities for the RWE secondary data department, Michael is responsible for the development of medical algorithms and the interpreting of big medical data sets of secondary data projects. These projects cover diverse topics such as Epidemiology, HEOR and Safety, and a broad range of therapy areas.

His interdisciplinary experience combines the three areas of expertise essential for secondary data-related studies: medical expertise, advanced project management skills, and a profound understanding of working with Real-World Data (RWD). With his in-depth knowledge of current opportunities, challenges, needs, and limitations of RWE and RWD, Michael is also ideally placed to consult regarding RWE in general and different study designs to bridge the growing need for leading-edge secondary data methodologies with classical post-authorization safety and efficacy studies.

Michael holds a doctorate and a state examination degree in Veterinary Medicine, both from the Ludwig Maximilian University of Munich, Germany.

PUBLICATIONS

Real-world psoriasis treatment patterns and disease burden in Germany, with a focus on biologics and apremilast: data from a German statutory health insurance database Pinter Andreas, Schulte Marcus, Kossack Nils, Marc Pignot, Michael Schultze, Feldhus Andrea JME: Journal of Medical Economics. 2025; VOL. 28, NO. 1, 207-220. 10.1080/13696998.2025.2452054. https://doi.org/10.1080/13696998.2025.2452054
Real-world treatment patterns and survival outcomes in patients with locally advanced squamous cell carcinoma of the head and neck in Germany using claims data Hering Kathrin, Kuhnt Thomas, Kossack Nils, Richter Lena M., Michael Schultze, Osowski Ulrike, Henkel Luisa, Gaupel Ann-Christin, Solbes Marie-Noelle, Zolyniak Bernard, Schoenherr Nancy Front. Oncol. 2025; Vol. 15:1547311. 10.3389/fonc.2025.1547311. https://doi.org/10.3389/fonc.2025.1547311
Prevalence of lupus nephritis among patients with systemic lupus erythematosus in Germany N Hunnicutt Jake, Michael Schultze, Garal-Pantaler Elena, Marc Pignot, Georgiou Mary Elizabeth, Gairy Kerry Nephrology Dialysis Transplantation, Volume 37, Issue Supplement_3, May. 2022; 10.1093/ndt/gfac071.036. https://doi.org/10.1093/ndt/gfac071.036
Clinical and economic burden of hypertrophic obstructive cardiomyopathy in Germany Sedaghat-Hamedani F., Zema C., Michael Schultze, Borchert J., Zhong Y., Bluhmki T., Krause T., Schmoelders J., Meder B. DGK Herztage 29.09 – 01.10.2022. 2022; 10.1007/s00392-022-02087-y. https://doi.org/10.1007/s00392-022-02087-y
Real-World Cost Difference in Patients With Psoriasis Initiating Apremilast vs. Secukinumab After Conventional Systemic Therapy Using German Sickness Fund Data Kossack Nils, Schoenfelder T., Michael Schultze, Marc Pignot, Mehta S., Nazareth T., Walzer S. DDK KOMPAKT 2020. JDDG Volume 18 Issue S1. 2020. 2020; 10.1111/ddg.14021. https://doi.org/10.1111/ddg.14021